Promising Drug to Treat Gastrointestinal Cancers

Translate to Spanish or other 102 languages!

The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.
The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By Mayo Clinic 

Newswise — PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.

Tanios Bekaii-Saab, M.D., an investigator from Mayo Clinic Cancer Center, has conducted research on adagrasib that has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations, including pancreatic cancer, biliary tract cancer and other upper gastrointestinal cancers. Dr. Bekaii-Saab recently presented the results of this research as part of the KRYSTAL-1 clinical trial (NCT03785249) at the American Society of Clinic Oncology’s Genitourinary Cancers Symposium.

- Advertisement -

“The prognosis for patients whose cancer harbors a KRAS gene mutation is particularly poor, and researchers’ attempts to target KRAS G12C, which represents less than 5% of all KRAS mutations in this group of cancers, have failed until only recently,” says Dr. Bekaii-Saab.

“Our data recently presented at ASCO GI (the symposium) showed that adagrasib not only inhibits cancers with a KRASG12C mutation effectively, but also showed promising clinical activity in patients with gastrointestinal cancers.”

Dr. Bekaii-Saab says the gastrointestinal cancers for all patients treated in this phase 2 cohort were controlled, with close to half showing evidence of significant and durable tumor shrinkage.

“These results were very impressive in treating a group of diseases that tend to have a particularly poor outcome,” says Dr. Bekaii-Saab. “We were pleasantly surprised by these findings, given that our previous experience with another similar agent was disappointing in this particular group of patients.”

- Advertisement -

He says research with adagrasib is ongoing. If these trends continue, the drug may eventually prove to be a new option for patients with pancreatic, biliary tract and other gastrointestinal cancers.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How to Avoid Getting Sick During Holiday Travel

Amid one of the busiest travel weeks of the year, an infectious disease specialist is sharing advice on how to lower your risk of getting sick when traveling this Thanksgiving.

STHS’s Latest “South Texas Healthy Living” Episode to Examine Bladder Health, Nov. 29

Healthy bladder function plays an important role in overall wellness, helping the body eliminate waste efficiently while supporting comfort, restful sleep and an active lifestyle.

Tips for Preventing and Treating Kitchen Cuts This Holiday Season

Preparing a holiday dinner can be as chaotic as it is joyous. A slip while chopping vegetables, peeling potatoes, or carving the turkey can happen even to the most experienced cooks.

STHS Behavioral to Host Webinar on Coping with Holiday Stress, Dec 3

The holiday season is often described as the most wonderful time of the year. However, for many people, it can also bring feelings of stress, sadness, anxiety and loneliness.
- Advertisement -